Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667244 | 1.00 | CES2 (0.50) | CES2CES1KMT2AHTTACKR3 | |
| SCHEMBL2523847 | 0.81 | F2R (0.37) | CES2CES1KMT2AHTT | |
| SCHEMBL2523845 | 0.81 | F2R (0.37) | CES2CES1KMT2AHTT | |
| SCHEMBL642910 | 0.75 | CES2 (0.61) | CES2CES1KMT2AHTTACKR3 | |
| Hydrochloric Acid SCHEMBL8393448 | 0.75 | CES2 (0.55) | CES2CES1 | |
| SCHEMBL1619995 | 0.74 | CES2 (0.50) | CES2CES1KMT2AHTTACKR3 | |
| SCHEMBL11570 | 0.73 | CES2 (0.68) | CES2CES1KMT2AHTTL3MBTL1 | |
| SCHEMBL29372550 | 0.73 | CES2 (0.68) | CES2CES1KMT2AHTTL3MBTL1 | |
| SCHEMBL21104626 | 0.71 | CES2 (0.45) | CES2CES1KMT2AMEN1 | |
| SCHEMBL6070552 | 0.71 | ALDH1A1 (0.55) | KMT2AALDH1A1L3MBTL1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | CES2 1836/4885CES1 3289/4885KMT2A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.